Table 1 Clinicopathological characteristics of 301 patients with PCa from TMA cohort

Age, years

 Mean ± SD

63.54 ± 7.63

 Range

42–85

BMI, kg/m²

 Mean ± SD

23.21 ± 3.26

 Range

16.23–31.12

T Stage, n (%)

 T2

140 (46.5)

 T3

128 (42.5)

 T4

33 (11.0)

N Stage, n (%)

 N0

160 (53.2)

 N1

141 (46.8)

M Stage, n (%)

 M0

273 (90.7)

 M1

28 (9.3)

Gleason grade group, n (%)

  ≤ 6

24 (8.0)

 3 + 4

40 (13.3)

 4 + 3

82 (27.2)

 8

83 (27.6)

  ≥ 9

72 (23.9)

Diagnostic PSA,ng/ml, n (%)

  < 10

18 (6.0)

 10–20

204 (67.8)

  > 20

79 (26.2)

Positive surgical margin, n (%)

 Yes

142 (47.2)

 No

159 (52.8)

Adjuvant therapy, n (%)

 Yes

161 (53.5)

 No

140 (46.5)

ARPC1A expression, n (%)

 (±)

93 (30.9)

 ( +)

114 (37.9)

 (+ +)

56 (18.6)

 (+ + +)

38 (12.6)